Literature DB >> 8695359

Syndecan-1 alterations during the tumorigenic progression of human colonic Caco-2 cells induced by human Ha-ras or polyoma middle T oncogenes.

P Levy1, A Munier, S Baron-Delage, Y Di Gioia, C Gespach, J Capeau, G Cherqui.   

Abstract

The products of ras and src proto-oncogenes are frequently activated in a constitutive state in human colorectal cancer. In this study we attempted to establish whether the tumorigenic progression induced by oncogenic activation of p21ras and pp60c-src in human colonic Caco-2 cells is associated with specific alterations of syndecan-1, a membrane-anchored proteoglycan playing a role in cell-matrix interaction and neoplastic growth control. To this end, we used Caco-2 cells made highly tumorigenic by transfection with an activated (Val 12) human Ha-ras gene or with the polyoma middle T (Py-MT) oncogene, a constitutive activator of pp60c-src tyrosine kinase activity. Compared with control vector-transfected Caco-2 cells, both oncogene-transfected cell lines (1) contained smaller amounts of membrane-anchored PGs; (2) exhibited decreased syndecan-1 expression at the protein but not the mRNA level; (3) synthesized 35S-labelled syndecan-1 with decreased specific activity; (4) produced a syndecan-1 ectodomain with a lower molecular mass and reduced GAG chain size and sulphation; and (5) expressed heparanase degradative activity. These results show that the dramatic activation of the tumorigenic potential induced by oncogenic p21ras or Py-MT/pp60c-src in Caco-2 cells is associated with marked alterations of syndecan-1 expression at the translational and post-translational levels.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695359      PMCID: PMC2074646          DOI: 10.1038/bjc.1996.376

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  54 in total

Review 1.  Proteoglycans: structure, function, and role in neoplasia.

Authors:  R V Iozzo
Journal:  Lab Invest       Date:  1985-10       Impact factor: 5.662

Review 2.  Biochemical interactions of tumor cells with the basement membrane.

Authors:  L A Liotta; C N Rao; U M Wewer
Journal:  Annu Rev Biochem       Date:  1986       Impact factor: 23.643

3.  Biological characterization and oncogene expression in human colorectal carcinoma cell lines.

Authors:  D L Trainer; T Kline; F L McCabe; L F Faucette; J Feild; M Chaikin; M Anzano; D Rieman; S Hoffstein; D J Li
Journal:  Int J Cancer       Date:  1988-02-15       Impact factor: 7.396

4.  Prevalence of ras gene mutations in human colorectal cancers.

Authors:  J L Bos; E R Fearon; S R Hamilton; M Verlaan-de Vries; J H van Boom; A J van der Eb; B Vogelstein
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

Review 5.  Proteoglycans and neoplasia.

Authors:  R V Iozzo
Journal:  Cancer Metastasis Rev       Date:  1988-04       Impact factor: 9.264

6.  Activation of pp60c-src protein kinase activity in human colon carcinoma.

Authors:  J B Bolen; A Veillette; A M Schwartz; V DeSeau; N Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  Cell surface proteoglycan of mouse mammary epithelial cells is shed by cleavage of its matrix-binding ectodomain from its membrane-associated domain.

Authors:  M Jalkanen; A Rapraeger; S Saunders; M Bernfield
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

8.  Cell surface proteoglycan associates with the cytoskeleton at the basolateral cell surface of mouse mammary epithelial cells.

Authors:  A Rapraeger; M Jalkanen; M Bernfield
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

9.  Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix.

Authors:  S Saunders; M Bernfield
Journal:  J Cell Biol       Date:  1988-02       Impact factor: 10.539

10.  Heparan sulfate proteoglycans from mouse mammary epithelial cells: localization on the cell surface with a monoclonal antibody.

Authors:  M Jalkanen; H Nguyen; A Rapraeger; N Kurn; M Bernfield
Journal:  J Cell Biol       Date:  1985-09       Impact factor: 10.539

View more
  8 in total

1.  The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer.

Authors:  J Kleeff; T Ishiwata; A Kumbasar; H Friess; M W Büchler; A D Lander; M Korc
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

2.  Syndecan-1 - A new piece in B-cell puzzle.

Authors:  L Kopper; A Sebestyén; M Gallai; I Kovalszky
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

3.  Syndecan-1 is up-regulated in ras-transformed intestinal epithelial cells.

Authors:  Z M Wong; B Choo; M Li; D J Carey; D F Cano-Gauci; R N Buick
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

Review 4.  Syndecans in tumor cell adhesion and signaling.

Authors:  DeannaLee M Beauvais; Alan C Rapraeger
Journal:  Reprod Biol Endocrinol       Date:  2004-01-07       Impact factor: 5.211

5.  Reduced expression of syndecan-1 affects metastatic potential and clinical outcome in patients with colorectal cancer.

Authors:  M Fujiya; J Watari; T Ashida; M Honda; H Tanabe; T Fujiki; Y Saitoh; Y Kohgo
Journal:  Jpn J Cancer Res       Date:  2001-10

6.  Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells.

Authors:  Sampath Kumar Katakam; Paride Pelucchi; Cinzia Cocola; Rolland Reinbold; Israel Vlodavsky; Burkhard Greve; Martin Götte
Journal:  Front Oncol       Date:  2020-05-14       Impact factor: 6.244

7.  Association of loss of epithelial syndecan-1 with stage and local metastasis of colorectal adenocarcinomas: an immunohistochemical study of clinically annotated tumors.

Authors:  Yosuke Hashimoto; Marek Skacel; Josephine C Adams
Journal:  BMC Cancer       Date:  2008-06-30       Impact factor: 4.430

Review 8.  Syndecans as modulators and potential pharmacological targets in cancer progression.

Authors:  Despoina Barbouri; Nikolaos Afratis; Chrisostomi Gialeli; Demitrios H Vynios; Achilleas D Theocharis; Nikos K Karamanos
Journal:  Front Oncol       Date:  2014-02-03       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.